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The Psychoactive Effects
of Psychiatric Medication:
The Elephant in the Room
Joanna Moncrieff, M.B.B.S.a; David Cohenb & Sally Porterc
Abstract —The psychoactive effects of psychiatric medications have been obscured by the presump-
tion that these medications have disease-specific actions. Exploiting the parallels with the psychoactive
effects and uses of recreational substances helps to highlight the psychoactive properties of psychi-
atric medications and their impact on people with psychiatric problems. We discuss how psychoactive
effects produced by different drugs prescribed in psychiatric practice might modify various disturb-
ing and distressing symptoms, and we also consider the costs of these psychoactive effects on the
mental well-being of the user. We examine the issue of dependence, and the need for support for peo-
ple wishing to withdraw from psychiatric medication. We consider how the reality of psychoactive
effects undermines the idea that psychiatric drugs work by targeting underlying disease processes,
since psychoactive effects can themselves directly modify mental and behavioral symptoms and thus
affect the results of placebo-controlled trials. These effects and their impact also raise questions about
the validity and importance of modern diagnosis systems. Extensive research is needed to clarify the
range of acute and longer-term mental, behavioral, and physical effects induced by psychiatric drugs,
both during and after consumption and withdrawal, to enable users and prescribers to exploit their
psychoactive effects judiciously in a safe and more informed manner.
Keywords — antidepressants, antipsychotics, prescription drug dependence, psychiatric drugs,
psychoactive effects, withdrawal effects
A characteristic and well-recognized property of
chemical substances used for recreational purposes is their
ability to produce altered states of consciousness and
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concomitant changes in behavior by virtue of their action
on the central nervous system. Drugs prescribed to treat
psychiatric disorders, including drugs commonly classified
as antidepressants, antipsychotics, anxiolytics, stimulants,
and drugs such as lithium and anticonvulsants used to treat
bipolar disorder, also modify normal mental processes and
behavior, but there has been a widespread tendency to
conflate these actions with a presumed effect on under-
lying disease processes. In this paper, we use the term
“psychoactive effects” to refer to the way some substances
produce altered cognitive and emotional states, which dif-
fer from the normal un-drugged state, and we distinguish
these effects from the putative disease-specific effects of
prescribed drugs. The distinction matters because, although
significant, the consequences of the psychoactive effects of
psychiatric medications are not well-recognized.
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Just like the various substances that are used recre-
ationally, each type of psychiatric medication induces a
distinctive altered mental and physical state, whose charac-
teristics depend largely on the nature of the drug ingested.
Numerous studies with human volunteers and countless
studies with animals document the range of ways that dif-
ferent psychiatric drugs impact on normal cognition, emo-
tion, and behavior (Baldessarini 1985). Although the term
“psychoactive” refers particularly to the mental alterations
produced by drugs, most of these alterations appear inti-
mately connected to physical or bodily effects, with many
“mental” effects having concomitant physical manifesta-
tions, together producing a “global” drug effect. Sedation,
for example, is both a mental and physical experience, and
arousal, like that produced by stimulant drugs, has mental
and physical aspects. It is likely that no psychoactive drug
produces only mental effects.
Some psychiatric medications produce pleasurable
psychoactive effects, or euphoria, and have consequently
become drugs that some people use recreationally and
sometimes excessively (leading to their designation as
possessing “abuse potential”). This has been the fate of
stimulants like amphetamine, introduced as a treatment for
depressive neurosis in the 1940s (Rasmussen 2006). Apart
from their use in attention-deficit hyperactivity disorder,
they are now most commonly associated with recreation
and performance enhancement. Benzodiazepines and the
related “Z-drugs” continue to be widely prescribed in gen-
eral practice and psychiatry, but have become popular black
market drugs, frequently used alongside opiates by those
with serious addiction problems. Anecdotal evidence sug-
gests that some other psychiatric medications, including
quetiapine and amitriptyline, have a modest “street” value
for their sedative effects.
Other psychiatric drugs are more often associated with
the experience of sharply unpleasant psychoactive effects
or dysphoria. This is most notably the case with the
neuroleptic or antipsychotic drugs, but selective serotonin
reuptake inhibitors (SSRIs), tricyclics, and lithium are also
generally disliked by volunteers (Dumont et al. 2005; Judd
et al. 1977). The fact that these drugs are not associated
with euphoria, and therefore do not usually induce craving
or become drugs of abuse, does not make them any less
“psychoactive” than recreational drugs, nor does it exclude
them from inducing physical dependence.
When novel drugs were introduced into psychiatry
in the 1950s, in contrast to nowadays, clinicians and
researchers expressed considerable interest in their charac-
teristic mind- and behavior-altering effects. They described
the striking state of mental restriction provoked by the early
neuroleptics, for example, which they contrasted with the
more familiar type of sedation produced by barbiturates:
. . .the apparent indifference, or delay in response to external
stimuli, the emotional and affective neutrality, the decrease
in both initiative and preoccupation without alteration of
conscious awareness or in intellectual faculties, constitute the
psychic syndrome due to treatment (Delay & Deniker 1952,
503-504).
Reports of early antidepressants, such as iproniazid,
also described their immediate psychoactive effects, which
appeared similar to those of stimulants (Crane 1956). Few
published accounts have described the subjective effects
induced by the many other drugs used as antidepres-
sants, however. Existing evidence suggests that tricyclics
are strongly sedative and also dysphoric (Dumont et al.
2005; Herrmann & McDonald 1978). SSRIs and venlafax-
ine appear to produce a state of lethargy and indifference,
coupled with an unpleasant state of agitation, tension, and
hostility in some people (Goldsmith & Moncrieff 2011).
An in-depth qualitative study describes the “essential lived
characteristic” of being on SSRIs as “increased distance
or disconnection between takers [and] their worlds” (Teal
2009, 19). Lithium produces dysphoria, lethargy, and cog-
nitive slowing and impairment in volunteers (Judd et al.
1977; Squire et al. 1980). Anticonvulsants, today part of the
standard maintenance treatment of bipolar disorders, show
a panoply of psychoactive effects, ranging from strong
sedation and cognitive slowing to anxiety and agitation
(Cavanna et al. 2010).
Although the immediate effects of common
psychoactive drugs are best known (e.g., the intoxi-
cation produced by alcohol), the continued use of drugs
with central nervous system activity has further conse-
quences for mental functioning. Firstly, tolerance to some
immediate effects may develop, and secondly, additional
mental or emotional alterations may occur, either as a
direct result of the continued presence of the drug in the
body, or of the body’s delayed adaptations to it. Tolerance
is known to develop to at least some effects of most recre-
ational substances. Though it has been little investigated
in relation to classes of drugs used in psychiatry, animal
research demonstrates that bodily adaptations develop
within days of continuous use of the antipsychotic drug
haloperidol, for example (Samaha et al. 2007). Late-onset
mental state changes are more difficult to ascribe with
certainty to drug ingestion, but we know that chronic
stimulant use can produce psychotic states, and long-
term alcohol use is associated with depression (Schuckit
1994), and some evidence suggests long-term use of
benzodiazepines is associated with dementia (Billioti
et al. 2012). The possibility of adverse psychological and
behavioral effects occurring after long-term use of other
psychiatric medications has periodically been suggested
(Barnhart et al. 2004; Myslobodsky 1993) but has received
little attention, despite the reasonable argument that
persistent use of any drug that produces alterations of
normal mental and physical states should be expected to
have long-term consequences.
Furthermore, discontinuation of most psychoactive
substances after chronic use produces mental and physical
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changes. Withdrawal from psychiatric medications, includ-
ing antidepressants and antipsychotics, is associated
with distinctive withdrawal or discontinuation syndromes,
which are suppressed by resumption of the drug (Judah
et al. 1961; Lejoyeux & Ades 1997). Within different
drug classes, drugs with a short half-life (including parox-
etine, venlafaxine, and clozapine) typically provoke the
most intense withdrawal symptoms (Goudie et al. 1999;
Hindmarch et al. 2000). Users own reactions’ to the phar-
macological effects of long-term drug use and subsequent
withdrawal add another layer of consequences. As with
several other psychoactive drugs, withdrawal symptoms
might be the most distinctive component of some people’s
psychiatric medication experience.
PSYCHOACTIVE EFFECTS AND MENTAL
SYMPTOMS
People use licit substances like caffeine, alcohol, and
nicotine to achieve a range of effects, including enhanc-
ing performance and sociability, producing relaxation, and
managing stress or everyday emotional discomfort. People
also sometimes use licit and illicit substances to combat
more severe symptoms of anxiety and depression, to sup-
press painful memories of trauma, and to help manage or
“escape” from psychologically or physically challenging
situations, like living on the street or dealing with chronic
stressors. Anecdotally, people are reported to have used
illicit substances like opiates to self-medicate psychotic
symptoms. Whether using drugs is ultimately helpful or
harmful to the user depends on a variety of interacting
factors, including the reason for using, the quantity taken,
the manner and duration of use, the characteristic physi-
cal and mental effects the drug produces, the situation and
personality of the individual user, the habits and lifestyle
associated with the drug’s use, as well as the social attitudes
and legal penalties attached to it.
The psychoactive properties of prescribed psychiatric
drugs also interact with the symptoms of mental disor-
ders, again in ways that depend at least on the nature of
the symptoms, the properties of the drug, and the social
circumstances of the user. For example, the particular qual-
ity of physical, mental, and emotional restriction produced
by neuroleptic or antipsychotic drugs was well recognized
in the 1950s to dampen intense psychotic thoughts and
experiences and other states of agitation and arousal, with-
out simply putting the patient to sleep (Deniker 1960;
Flugel 1959). This theory of neuroleptic action is supported
by more recent research that confirms that antipsychotic
drug treatment more commonly reduces the intensity or
“salience” of psychotic symptoms, rather than removing
them altogether (Mizrahi et al. 2005). Such results are con-
firmed by patients’ descriptions of how the psychoactive
effects of antipsychotics reduce psychotic symptoms while
also suppressing other aspects of mental activity (Moncrieff
et al. 2009). These characteristic effects of neuroleptics
make them usually effective, although not necessarily safe,
agents for the practice of rapid tranquilisation (TREC
Collaborative Group 2003) and for the control of symptoms
of mania (Prien, Caffey & Klett 1972). These effects may
also be seen as useful in other circumstances involving
impulsive and aggressive behavior where alternative strate-
gies are lacking or difficult to implement, including use
in people with dementia or people who are considered
personality disordered. Tolerance and other factors may
counteract their effects in some of these situations, however
(Maher et al. 2011). The ability to flatten emotions may
explain why neuroleptics are distinguished from placebo in
trials of depression (Robertson & Trimble 1982), and this,
combined with their sedative effects, would also explain
why many people find them helpful in anxiety (Maher et al.
2011). The usefulness of neuroleptics is limited by their
distinctly dysphoric effects, however, as well as their seri-
ous physical complications, which would be expected to tilt
the balance against their use for all but the most severely
disabling conditions. Other drugs with sedative properties
may be equally useful in some of these situations. Thus,
acute mania is known to respond to lithium and sodium
valproate (Bowden et al. 1994) and to benzodiazepines
(Chouinard 1988).
Drugs commonly called antidepressants produce vari-
ous psychoactive effects. The sedative effects of tricyclics
may be useful for insomnia, anxiety, or agitation and these
effects are not restricted to people with a diagnosis of
depression, as reflected in the continuing popularity of
low-dose tricyclic prescribing (Ilyas & Moncrieff 2012).
Benzodiazepines may be preferable on safety grounds,
however, if temporary sedation is what is intended. The
benefits of other antidepressants are not so clear. The emo-
tional flattening or disengagement described in relation to
SSRIs may reduce feelings of depression, but the gener-
alized nature of this effect, and its association with loss
of libido (Goldsmith & Moncrieff 2011), would argue
against the utility of these drugs in depression. We can
speculate on how other psychoactive drugs — such as
amphetamines, which induce euphoria and were long used
as antidepressants (Rasmussen 2006), and opiates, which
produce emotional anesthesia (Savvas et al. 2012) — might
reduce or mask depressive symptoms. Drugs that pro-
duce short-term mood elevation, however, typically require
increasing dose to maintain this effect and entail dysphoria
when they are discontinued. No known substance appears
capable of producing long-term mood elevation, which
hints at the misleading nature of the term “antidepressant”
(Moncrieff & Cohen 2006).
Use of psychiatric drugs is only worthwhile if the
benefits outweigh the harms. Calculating a harm/benefit
ratio is a complex undertaking, however, given that what
is considered harmful or beneficial varies according to
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many factors, including the perspective of the observer and
the phase of treatment. Individuals will also have differ-
ent subjective responses to prescribed drugs, just as people
respond differently to recreational substances. The lack
of data about the consequences of the long-term use of
prescribed psychiatric medications on the full range of
human emotions and cognitive functions further hampers
a thorough and balanced assessment of their value or oth-
erwise, especially since they are normally prescribed for
months and often for years. Moreover, it is often the subtle
and easily overlooked aspects of drug treatment that users
find most troubling. The mental effects of antipsychotics,
for example, can be experienced as more unpleasant and
impairing than their physical effects, and can interfere
with people’s ability to carry out daily tasks (Awad 1993;
Moncrieff et al. 2009). In a study of SSRIs, mental effects
led to drug discontinuation as often as physical effects
(Bolling & Kohlenberg 2004).
On the other hand, some people actively seek the mind-
altering properties of prescribed or illicit substances in
order to manage distressing emotional states, and they may
use both sorts of drugs simultaneously. Use of multiple pre-
scribed and illicit psychoactive substances risks producing
compound and unpredictable effects on normal function-
ing and symptoms. Although there is a general recognition
that the use of recreational substances can become detri-
mental to a person’s mental as well as physical health,
such effects are rarely considered when psychiatric med-
ications are prescribed. It is clear that the mind-numbing
effects of psychoactive drugs like opiates and alcohol can
constitute a barrier to addressing underlying psychologi-
cal or personal issues, or environmental adversity, and to
forming the supportive social relationships that improve
the chances of long-term recovery. Just as substance mis-
use services encourage people to identify what function
their drug use satisfies, and to develop less harmful strate-
gies for dealing with problems, it may be preferable for
psychiatric services, in some instances, to help individ-
uals identify alternative ways of coping with emotional
distress rather than prescribing medication. As with the
misuse of recreational substances, identifying the func-
tion the drug fulfills and the pharmacological effects that
facilitate its function may help people to develop alter-
native strategies for coping with adverse emotions and
experiences.
PSYCHOACTIVE EFFECTS AND MECHANISM
OF ACTION
Drugs with psychoactive effects, whether taken for
therapeutic or recreational purposes, will affect the
thoughts, feelings, and behaviors that are constitutive of
conditions referred to as mental disorders. They will there-
fore impact on self- or clinician-reported measures of
psychological symptoms in placebo-controlled trials. Yet
because these psychoactive effects have not been con-
trolled or accounted for in the vast majority of clinical
studies of psychiatric medications, no one is in a position
to state whether these drugs have, in fact, any other type
of reliable action relevant to the treatment of symptoms.
In particular, we do not know whether psychiatric med-
ications also modify the still-unknown physiological or
biochemical processes that are hypothesized to give rise to
the symptoms of particular mental disorders as delineated
in current diagnostic manuals. We do not have evidence that
psychiatric drugs exert targeted, disease-specific effects.
Studies that compare a drug thought to have a
disease-specific action with a drug that produces similar
psychoactive effects but is not thought to act on the dis-
ease process might be able to clarify how a drug “works.”
Even then, there would remain the question of whether
the altered states produced by the two drugs were really
equivalent. In any case, there have been few such stud-
ies and those that exist provide little confirmation that
psychiatric drugs exert a disease-specific action, indepen-
dent of their psychoactive properties. Two early studies
found that antipsychotics were superior to a barbiturate
in people with psychosis, but it had already been noted
that antipsychotics produce a different sort of altered state
from barbiturates (Casey et al. 1960a; Casey et al. 1960b).
Two studies compared lithium to antipsychotics for the
treatment of various psychotic states and neither showed
any difference between the drugs’ effects on people with
different diagnoses (affective psychosis compared with
schizophrenic disorders) (Braden et al. 1982; Johnstone
et al. 1988). Although one of the studies claimed to show a
differential effect on individual symptoms, this was only
achieved through a complex analysis that left numbers
small and most differences statistically non-significant, and
did not compare effects of the drugs directly (Johnstone
et al. 1988). Overall, several old studies comparing opi-
ates and benzodiazepines with antipsychotics for psychosis
were unable to distinguish the different sorts of drugs
(Abse et al. 1960; Wolkowitz & Pickar 1991). Clinical tri-
als with a wide array of psychoactive substances that are
not usually thought of as antidepressants, including stim-
ulants, benzodiazepines, and neuroleptics, show effects on
depression rating scales similar to those produced by drugs
classified as antidepressants (Moncrieff 2001). On the other
hand, the idea that a delay occurs between the start of psy-
chiatric medication and the subject’s therapeutic response
might argue against immediate psychoactive effects of
psychiatric medication explaining part of the therapeutic
effects rated in clinical trials. However, recent analyses of
antipsychotic and antidepressant trials suggest that drug
effects occur quite early (Agid et al. 2003; Walsh et al.
2002).
“Amplified” placebo effects may also contribute to
drug-placebo differences in randomized controlled trials
Journal of Psychoactive Drugs 412 Volume 45 (5), November – December 2013
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(Moncrieff, Wessley & Hardy 1998). Apart from their
direct action on symptoms, psychoactive and physical
effects may reveal to researchers and participants in
placebo-controlled trials who is receiving active medica-
tion and who is not, causing the placebo effect of medica-
tion to be amplified and to exceed that produced by inert
placebo tablets. Placebo-controlled studies cannot there-
fore in principle establish whether a drug works, if it
does, by reversing an underlying pathological process or
by inducing an altered mental and physical state which may
directly affect manifestations of the disorder or subvert the
double-blind design of clinical trials.
DEPENDENCE
It is now accepted that all major classes of psychiatric
medication produce distinctive withdrawal effects which
mostly reflect their pharmacological activity. These effects
are significant not only because they can prevent some-
one from stopping medication when they do not need it or
want it anymore, but also because they may be—and prob-
ably often are—mistaken for signs of relapse (Moncrieff
2006). This creates a situation whereby patients become
psychologically as well as physically dependent on their
medication, since they (and their prescribers too) may come
to believe that they cannot manage without it.
That drugs like antidepressants and antipsychotics are
being prescribed for longer and longer periods suggests
that some people may find it difficult, either for physi-
cal or psychological reasons, to stop medication once it
is started (Moore et al. 2009; Prah et al. 2012). This is of
particular concern given the serious adverse consequences
associated with long-term use of drugs like antipsychotics,
which include cardiac complications, metabolic dysfunc-
tion, and neurological damage such as tardive dyskinesia
(Newcomer & Haupt 2006; Ray et al. 2009; Tarsy et al.
2011). More help is needed to support people who wish
to stop psychiatric medication when it is considered safe
to do so, and further research should clarify the full range
of withdrawal effects and their likely duration, since there
are reports of protracted and disabling withdrawal states
following the discontinuation of some prescribed drugs
(Modell 1997; Precourt et al. 2005). General physicians
and healthcare workers need more information and training
about devising tapering schedules, recognizing withdrawal-
related symptoms and distinguishing them from prior
symptoms, in order to improve their confidence and ability
to support people who wish to withdraw from prescribed
medication (Cohen 2007). Therapy focusing on finding
alternative techniques for managing emotional states such
as that provided in drug and alcohol rehabilitation pro-
grams may be necessary for people who have been on
mind-, mood-, and behavior-altering drug treatment for
long periods.
CONCLUSIONS
Approaching psychiatric medications as drugs which
produce immediate and delayed psychoactive effects, and
which induce tolerance and dependence, fundamentally
differs from the conventional understanding that suggests
these drugs exert specific actions on (presumed) underly-
ing disease processes. According to the conventional view,
the drugs’ psychoactive properties are merely incidental
“side-effects.” Despite six decades of intensive research in
neuropharmacology, however, there is a lack of evidence
that psychiatric drugs have a disease-specific action inde-
pendent of their demonstrable psychoactive effects. These
facts suggest that a radical change of thinking may be nec-
essary about the nature, possibilities, and limitations of
psychiatric drug treatment. Lessons from the use and mis-
use of other psychoactive substances can help to enlighten
us about the broad range of behavioral effects that different
psychiatric medications are likely to exert, and how these
effects might interact with the psychological, behavioral,
and other problems we call mental disorders.
This reorientation would demand that people pre-
scribed psychiatric medicaments are treated as informed
consumers, rather than passive recipients of diagnosis-
driven prescribing. The user’s subjective experience should
guide the use of psychiatric medications in a collaborative
dialogue with the prescriber, rather than changes in des-
ignated symptoms or clusters of symptoms. Much more
information is required, however, on the behavioral phar-
macology of psychiatric drugs, including all the mental,
behavioral, and physical effects they induce in the acute
phase and long-term, and during consumption and with-
drawal. Data of this sort is likely to lead to revision of
manufacturer-recommended dosing schedules which take
no account of the quantitative relationship between dose
and subjectively-experienced effects, derived as they are
from fixed-dose studies and from trials narrowly focus-
ing on clinician-rated target symptoms. We also need to
assess further how the various drug-induced effects might
interact with particular psychological symptoms in differ-
ent circumstances and from the point of view of different
observers. Only when we appreciate the nature of psy-
chiatric drugs as psychoactive substances can we start
to accumulate the knowledge necessary to enable pre-
scribers and consumers to use these drugs safely and
effectively.
Re-orienting drug therapy in this manner also raises
questions about the validity and relevance of diagnos-
tic systems such as the recently published DSM-5. The
idea that psychiatric pharmaceuticals exert a disease- or
disorder-specific action has long been one of the principal
justifications for modern classification (Spitzer 1976), but
as we indicate above, there is in fact no compelling evi-
dence to support this supposition. Using psychiatric drugs
explicitly for their psychoactive effects implies the need for
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a different understanding of the nature of psychiatric prob-
lems, one that focuses not on diagnoses or syndromes that
are presumed to represent the manifestations of a discrete
underlying pathology, but to an individualized apprecia-
tion of the nature, context, and origins of each person’s
particular behavioral and emotional difficulties. Such an
approach would break the alleged link between diagnoses
and treatment, and enable a frank discussion about the pur-
pose and ethics of the already frequent “off-label” use of
prescribed psychoactive medications, such as their use for
behavioral control in children and the elderly.
Acknowledging the psychoactive effects of psychi-
atric medication naturally also raises the thorny question
of why some psychoactive drugs are prohibited and others
not. Although this topic is beyond the scope of this paper,
we note that some drugs which are used recreationally
for their euphoric effects appear to be useful agents in
various situations: benzodiazepines for their effects on
emotional and behavioral disturbance; stimulants for the
performance of tasks requiring unusual endurance; and
possibly hallucinogens, when people seek insights in ther-
apeutic situations or during end-of-life care (Grob et al.
2011). When the nature of the useful effect is identi-
fied, however, other non drug-based ways of achieving
the same result may be devised that avoid the potentially
harmful consequences of drug exposure (Macready 2012).
Similarly, recognizing the psychoactive effects of psychi-
atric medications may facilitate the development of alter-
native strategies for ameliorating mental distress and also
draw attention to some potentially anti-therapeutic conse-
quences of using psychoactive substances as therapeutic
agents.
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